


# **Maternal/Pediatric Respiratory Syncytial Virus (RSV) Work Group**

**Sarah S. Long, MD**  
**Chair, Maternal/Pediatric RSV Work Group**

**ACIP General Meeting**  
**February 23, 2023**



# Work group members

## ACIP Members

Sarah Long (chair)

Pablo Sanchez

Oliver Brooks

Camille Kotton

## Ex Officio Members

Rachel Zhang (FDA-CBER)

Nicholas Geagan (FDA-CBER)

Judy Beeler (FDA-CBER)

Yodit Belew (FDA-CDER)

Prabha Viswanathan (FDA-CDER)

Sonnie Kim (NIH-NIAID)

April Killikelly (Public Health Agency of Canada)

Winnie Siu (Public Health Agency of Canada)

Valerie Marshall (OIDP/OASH)

Jessica Lee (CMS/CMCS)

Terry Dalle-Tezze (HRSA)

## Consultants

Cody Meissner (Dartmouth Geisel School of Medicine)

Helen Chu (University of Washington)

Natasha Halasa (Vanderbilt University)

Denise Jamieson (Emory University School of Medicine)

Daniel Feikin (World Health Organization)

Carol Baker (University of Texas Health Science Center)

Kevin Ault (Western Michigan University)

## Liaisons

James McAuley (IDSA)

Patsy Stinchfield (NFID)

Brenna L. Hughes (ACOG)

Nicole Chaisson (AAFP)

Sean O'Leary (AAP)

Jennifer Schuster (PIDS)

Molly Howell (AIM)

## CDC

Katherine Fleming-Dutra (co-lead)

Jefferson Jones (co-lead)

Meredith McMorrow

Claire Midgley

Mila Prill

Fiona Havers

Natalie Thornburg

Tami Skoff

Aron Hall

Angie Campbell

Ismael Ortega-Sanchez

Michael Melgar

Tamara Pilishvili

Amanda Payne

Melissa Coughlin

Nicole Dowling

Jamison Pike

Noelle Molinari

Lauren Roper

Pragna Patel

Amber Winn

Andrea Sharma

Chris Taylor

## GRADE/EtR consultants

Doug Campos-Outcalt

Rebecca Morgan

# Previous maternal/pediatric RSV ACIP presentations

- Epidemiology and burden of RSV in infants
  - RSV seasonality in United States
  - Outpatient, emergency department (ED) visits, hospitalizations, and deaths
- Virology and immunology of RSV
- Safety and efficacy of nirsevimab
  - Phase 3 study in infants born  $\geq 35$  weeks gestation (initial and updated results)<sup>1</sup>
  - Phase 2b study in infants born 29–34 weeks gestation
  - Phase 2/3 safety and pharmacokinetic study in infants at high risk of RSV disease<sup>2</sup>

<sup>1</sup>Initial results from start of trial until pause for COVID-19 pandemic and updated

<sup>3</sup> results that included entire sample. <sup>2</sup>Eligible for palivizumab.

# Agenda: Thursday February 23, 2023

- Cost effectiveness analysis for nirsevimab – CDC model Dr. David Hutton (University of Michigan)
- Cost effectiveness analysis for nirsevimab – Comparison to manufacturer model Dr. Ismael Ortega Sanchez (CDC)
- Evidence to Recommendations framework for nirsevimab Dr. Jefferson Jones (CDC)
- Clinical considerations for nirsevimab Dr. Jefferson Jones (CDC)
- Safety and Efficacy of RSV Bivalent PreF Maternal Vaccine Dr. Iona Munjal (Pfizer)
- Workgroup considerations Dr. Katherine Fleming-Dutra (CDC)

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

